MEDICINOVA INC

Overview

Compare with Can Fite Biopharma, Selecta Biosciences (United States) or America Great Health, or pick any stock.

• TickerMNOV on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersLa Jolla, California¹
• Incorporated inDE²
• Business address4275 Executive Square, Suite 300, La Jolla, Ca 92037²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

The MediciNova logo is a registered trademark of MediciNova, Inc. All other product and company names are registered trademarks or trademarks of their respective companies.³ From its latest annual report

Corporate structure

MEDICINOVA INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MEDICINOVA INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

In December 2017, we executed a sublease agreement for our San Diego headquarters (Sublease) with Cardinal Health 127 Inc., the sublessor, to which Irvine Company, the master lessor, had provided its consent. The Sublease was for approximately 4,400 square feet and had a term of four years and one month. We have extended this Sublease for an additional 5 years through January 31, 2027.

In June 2005, we leased office space in Tokyo, Japan under a non-cancelable operating lease with an original expiration date of May 2013 and an auto-renewal two-year extension. The lease was renewed in May 2023 and has a term of two years with an auto-renewal, two year extension. In April 2024, we provided notice to terminate the previous lease agreement, effective October 2024, and in May 2024, we entered into a new lease agreement, effective June 2024, for a different office space for the Tokyo location. The new lease has an initial lease term of 12 months ending May 2025 with an option to extend for an additional two months, after which there will be automatic two-month renewals until the lease is terminated.

Item 2 of the 10-K filed Mar 10, 2026.³

Leadership

Who has led MEDICINOVA INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerYuichi Iwaki Jan 6, 2006 to now¹²
• PresidentYuichi Iwaki Jan 9, 2008 to now¹³
• Chief financial officerJason J. Kruger Jun 27, 2022 to Jun 27, 2022¹⁴
• Chief financial officerDouglas Paulin Aug 10, 2021 to Aug 10, 2021¹⁵
• Chief financial officerEdward C. Stepanow Jr. Jun 24, 2020 to Jun 24, 2020¹⁶
• Chief financial officerCarla Reyes Jun 5, 2018 to Jun 5, 2018¹⁷
• Chief financial officerRyan J. Selhorn Mar 31, 2016 to Mar 31, 2016¹⁸
• Chief financial officerYuichi Iwaki Dec 3, 2013 to Dec 3, 2013¹⁹
• Chief financial officerMichael Denis Coffee Mar 31, 2011 to Mar 31, 2011²⁰
• Chief financial officerMichael J. Gennaro Sep 19, 2011 to Sep 19, 2011²¹
• Chief financial officerShintaro Asako Nov 14, 2006 to Feb 2, 2010²²

Timeline

1. Sep 28, 20268-K Entered a material agreement⁴⁸
2. Sep 2, 20268-K Ended a material agreement⁴⁹
3. Aug 19, 20268-K Executive or director change⁵⁰
4. Jun 24, 20268-K Shareholder vote⁵¹
5. Feb 20, 20268-K Results of operations⁵²
6. Dec 30, 20258-K Entered a material agreement⁵³
7. Aug 1, 20258-K Entered a material agreement⁵⁴
8. Jun 18, 20258-K Shareholder vote⁵⁵
9. Mar 11, 20258-K Regulation FD disclosure⁵⁶
10. Jun 12, 20248-K Shareholder vote⁵⁷
11. Apr 1, 20248-K Executive or director change⁵⁸
12. Aug 7, 20238-K Executive or director change⁵⁹
13. Jan 6, 2006New chief executive Yuichi Iwaki becomes CEO¹²

Calendar

Coming up

1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.06) a share, on Nov 12, 2025.⁶⁰

When it reported results

1. Feb 20, 2026Reported quarterly or annual results⁵²

Drug trials and FDA: coming up

1. Dec 31, 2026Phase 2 trial readout expected Phase 2 trial of MN-001 in Diabetes Mellitus, Type 2: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT05464784).⁶¹
2. Apr 2027Phase 2/3 trial readout expected Phase 2/3 trial of MN-166 in Amyotrophic Lateral Sclerosis: primary completion expected Apr 2027 (ClinicalTrials.gov NCT04057898).⁶²

Drug trials and FDA: recently

1. Dec 7, 2020Phase 2 trial completed Phase 2 trial of MN-001 in Idiopathic Pulmonary Fibrosis: primary completion Dec 7, 2020, results posted Jan 23, 2026 (ClinicalTrials.gov NCT02503657).⁶³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

113 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 18 major events, 38 insider forms, 2 large holders, 34 other. The latest 20:

1. Sep 29, 20264 EDGAR
2. Sep 29, 2026SCHEDULE 13D/A EDGAR
3. Sep 28, 20268-K EDGAR
4. Sep 2, 20268-K EDGAR
5. Aug 19, 20268-K EDGAR
6. Aug 13, 202610-Q EDGAR
7. Jun 25, 20264 EDGAR
8. Jun 25, 20264 EDGAR
9. Jun 25, 20264 EDGAR
10. Jun 24, 20268-K EDGAR
11. May 14, 202610-Q EDGAR
12. Apr 29, 2026ARS EDGAR
13. Apr 29, 2026DEFA14A EDGAR
14. Apr 29, 2026DEF 14A EDGAR
15. Apr 20, 2026PRER14A EDGAR
16. Apr 17, 2026PRE 14A EDGAR
17. Mar 10, 202610-K EDGAR
18. Feb 20, 20268-K EDGAR
19. Jan 20, 20264 EDGAR
20. Jan 20, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 0 buys and 5 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• 3D Investment Partners Pte. Ltd.SCHEDULE 13D/A, 2 filings Jul 12, 2022 to Sep 29, 2026⁶⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MEDICINOVA INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARMEDICINOVA INC¹
• CIK0001226616
• Employer ID (EIN)33-0927979³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address4275 Executive Square, Suite 300, La Jolla, CA 92037¹
• Phone858-373-1500¹
• Shares outstanding49,221,246 as of Aug 11, 2026¹¹
• Public float$62.4M as of Jun 30, 2025³
• AuditorBDO USA, P.C., San Diego, California PCAOB ID 243; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceApr 8, 2003¹
• Filings878 in all: 8-K (277), 4 (243), 10-Q (65), 3 (43), DEF 14A (23), 10-K (22), SC 13G/A (21), 424B5 (16)¹
  All 42 form types

  ARS (13), CORRESP (12), EFFECT (12), SC 13G (12), UPLOAD (12), 425 (11), DEFA14A (11), S-3 (10), 4/A (8), 424B3 (7), S-8 (7), PRE 14A (5), S-1/A (5), S-1 (4), S-3/A (4), S-8 POS (4), SC 13D (4), SC 13D/A (4), S-4/A (3), 424B1 (2), 8-A12G (2), CT ORDER (2), PRER14A (2), REGDEX (2), 10-K/A (1), 10-Q/A (1), 3/A (1), 8-A12B (1), 8-A12G/A (1), CERTNAS (1), POS AM (1), REGDEX/A (1), S-4 (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (10-K) Mar 10, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Apr 29, 2026
  Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 10, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks MEDICINOVA INC names in Item 1A of its 10-K filed Mar 10, 2026: 49 risks under these headings, as written.³

• Risks Related to Our Business and Industry
• We have incurred significant operating losses since our inception and expect that we will incur continued losses for the foreseeable future.
• We will need to obtain additional funding to complete the development and any commercialization of our product candidates, if approved. If we fail to obtain this capital necessary to fund our operations, we will be forced to significantly delay, scale back or eliminate some or all of our clinical or regulatory activities or other operations.
• We do not have any products that are approved for commercial sale and therefore currently generate no revenues from sales of any products and may never generate any revenues from product sales or be profitable in the foreseeable future, if ever.
• We are largely dependent on the success of our MN-166 (ibudilast) and MN-001 (tipelukast) product candidates and we cannot be certain that these product candidates will receive regulatory approval or be successfully commercialized.
• Because the results of early clinical trials are not necessarily predictive of future results, our product candidates we advance into clinical trials in any indication may not have favorable results in later clinical trials, if any, or receive regulatory approval.
• Interim and preliminary "top-line" data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data.
• Our attempts to develop MN-001 (tipelukast) in Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD) may detract from our efforts to develop other product candidates and may limit the effectiveness of our product development efforts as a whole.
• In order to commercialize a therapeutic drug successfully, a product candidate must receive regulatory approval after the successful completion of clinical trials, which can be lengthy, complex and costly, have a high risk of failure and can be delayed or terminated at any time.
• We are subject to stringent regulation of our product candidates, which could delay the development and commercialization of our product candidates.
• Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.
• We have received Fast Track and/or Orphan Drug designation for certain of our product candidates and may seek such designation, breakthrough therapy and/or priority review for other product candidates in the future. We may not receive such designations, and even if we do, we may not maintain such designations, and such designations may not lead to faster development, regulatory review or approval, and will not increase the likelihood that the product candidate will receive marketing approval.

Legal proceedings

We are not involved in any material legal proceedings as of the date of this report. We may become involved in various disputes and legal proceedings which arise in the ordinary course of business. Our assessment of the likely impact of our pending litigation may change over time. An adverse result in any of these matters may occur which could harm our business and result in a material liability.

The opening of Item 3, Legal Proceedings.³